Plumb Pharmaceuticals announced recently that it received an investment from the Winnow Fund earlier this year.

The company did not reveal the investment amount.

Plumb Pharmaceuticals is currently developing its Advanced Quantload lipid-based extended-release drug technology with naltrexone, a drug commonly used to treat alcohol and opioid addiction.

“Opioid deaths have reached a record high in the U.S.,” President and CEO Alex Vodenlich said in a statement. “Our goal with this new formulation of naltrexone is to extend the effective duration significantly to reduce chronic relapsing of individuals in treatment.”